Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: A prospective, single-institute study

Cancer

Volumn 120, Issue 10, 2014, Pages 1471-1481

  Serizawa, Masakuni ^a   Koh, Yasuhiro ^a   Kenmotsu, Hirotsugu ^a   Isaka, Mitsuhiro ^a   Murakami, Haruyasu ^a   Akamatsu, Hiroaki ^a,b   Mori, Keita ^a   Abe, Masato ^a   Hayashi, Isamu ^a   Taira, Tetsuhiko ^a   Maniwa, Tomohiro ^a   Takahashi, Toshiaki ^a   Endo, Masahiro ^a   Nakajima, Takashi ^a   Ohde, Yasuhisa ^a   Yamamoto, Nobuyuki ^a,b  

^a SHIZUOKA CANCER CENTER   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

driver mutation; lung adenocarcinoma; molecular targeted therapeutics; multimutational profiling; personalized cancer medicine

Indexed keywords

ERIBULIN; ERLOTINIB;

ADULT; AGED; AKT1 GENE; ALK GENE; ARTICLE; BRAF GENE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; EGFR GENE; FEMALE; FGFR1 GENE; FGFR2 GENE; GENE AMPLIFICATION; GENE DELETION; GENE FUSION; GENETIC ASSOCIATION; GENETIC CORRELATION; GENOTYPE; HUMAN; HUMAN TISSUE; JAPANESE (PEOPLE); LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MEK1 GENE; MET GENE; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE NEU; PIK3CA GENE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PTEN GENE; RET GENE; ROS1 GENE; TREATMENT FAILURE;

DRIVER MUTATION; LUNG ADENOCARCINOMA; MOLECULAR-TARGETED THERAPEUTICS; MULTIMUTATIONAL PROFILING; PERSONALIZED CANCER MEDICINE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING;

EID: 84899910662     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28604     Document Type: Article

References (28)

1. Pao W, Girard N,. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011; 12: 175-180.
2. Oxnard GR, Binder A, Janne PA,. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol. 2013; 31: 1097-1104.
3. Gadgeel SM,. New targets in non-small cell lung cancer. Curr Oncol Rep. 2013; 15: 411-423.
4. Li T, Kung HJ, Mack PC, Gandara DR,. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013; 31: 1039-1049.
5. Thomas A, Rajan A, Lopez-Chavez A, Wang Y, Giaccone G,. From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. Ann Oncol. 2013; 24: 577-585.
6. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013; 8: 823-859.
7. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-1703.
8. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011; 12: 1004-1012.
9. Cardarella S, Ortiz TM, Joshi VA, et al. The introduction of systematic genomic testing for patients with non-small-cell lung cancer. J Thorac Oncol. 2012; 7: 1767-1774.
10. Johnson BE, Kris MG, Kwiatkowski DJ, et al. Clinical characteristics of planned 1000 patients with adenocarcinoma of lung (ACL) undergoing genomic characterization in the US Lung Cancer Mutation Consortium (LCMC) [Abstract]. J Thorac Oncol 2011; 6 (suppl 2): abstract O16.01.
11. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012; 18: 375-377.
12. Li C, Fang R, Sun Y, et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One. 2011; 6: e28204.
13. Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011; 22: 2616-2624.
14. Yip PY, Yu B, Cooper WA, et al. Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma. J Thorac Oncol. 2013; 8: 408-414.
15. Su Z, Dias-Santagata D, Duke M, et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn. 2011; 13: 74-84.
16. Mitsudomi T, Suda K, Yatabe Y,. Surgery for NSCLC in the era of personalized medicine. Nat Rev Clin Oncol. 2013; 10: 235-244.
17. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009; 27: 4247-4253.
18. Tomizawa K, Suda K, Onozato R, et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer. 2011; 74: 139-144.
19. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011; 29: 2046-2051.
20. Li H, Pan Y, Li Y, et al. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer. 2013; 79: 8-13.
21. Sun Y, Ren Y, Fang Z, et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol. 2010; 28: 4616-4620.
22. Gautschi O, Pauli C, Strobel K, et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol. 2012; 7: e23-e24.
23. Peters S, Michielin O, Zimmermann S,. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol. 2013; 31: e341-e344.
24. De Greve J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer. 2012; 76: 123-127.
25. University Hospital Medical Information Network (UMIN). http://www.umin.ac.jp/english/.
26. Koh Y, Kenmotsu H, Serizawa M, et al. Identification of actionable mutations in surgically resected tumor specimens from Japanese patients with non-small cell lung cancer by ultra-deep targeted sequencing [Abstract]. J Clin Oncol. 2013; 31 (suppl): abstract 7572.
27. Chaft JE, Arcila ME, Paik PK, et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther. 2012; 11: 485-491.
28. Santelmo C, Ravaioli A, Barzotti E, et al. Coexistence of EGFR mutation and ALK translocation in NSCLC: Literature review and case report of response to gefitinib. Lung Cancer. 2013; 81: 294-296.